Gastrointestinal Surgery Study Group 2001

Summary

Gastric cancer is one of the most common malignace worldwide, which caused a dramatically death rate, especially in east Asian, such as Japan , South Korea and China. Although the treatment of gastric cancer has a large improvement, such as radiotherapy, chemotherapy and immunotherapy, surgery is yet the mainstream method for the curable malignace without distant metastasis. As the innovation of treatment in gastric caner, laprascopic has gain its popularity owing to its equivalent oncologic outcomes, earlier oral feeding, shorten postopertative of hospital length,compared with open surgery. Depite it has several advantages, the defect of laparascopic surgery is still obvious, such as 2D surgical field, lack of inverse haptic feedback, Inflexible equipment.

D2 Lymph node dissection associated with laparascopic gastronomy is still regard as standard surgical procedure for the gastric cancer patient whose tumor stage was evaluated in advance stage. As we known that the distribution of lymph nod is accompanied with blood vessels, even for well-trained surgeon, the procedure lymph node dissection is a challenging and tough work. Computed Tomography Angiography(3D-CTA), as a emerging technology, is gradually receive the surgeon's attention for its remedy characteristic to the defect of laparascopic surgery, which can visually display the distribution and type of perigastric artery, resulting in decresing the difficulty and risk of surgery.

The aim of the study is to investigate the clinincal outcomes for the patient with BMI ≥25 kg/㎡who underwent laparascopic or robotic gastronomy using CTA to evaluate the type of perigastric artery.

Conditions

• Gastrostomy
• Computed Tomography Angiography
• Clinical Outcome

Interventions

DEVICE

CT angiography（CTA）

The CTA group was peformed upper abdomen enhenced and CT Angiography before surgery

Sponsors & Collaborators

• Qilu Hospital of Shandong University

  collaborator OTHER

• Shandong Provincial Hospital

  collaborator OTHER_GOV

• Qianfoshan Hospital

  collaborator OTHER

• Yantai Yuhuangding Hospital

  collaborator OTHER

• Weifang Medical University

  collaborator OTHER

• Weifang People's Hospital

  collaborator OTHER

• Jining First People's Hospital

  collaborator OTHER

• Weihai Municipal Hospital

  collaborator OTHER

• Weihai Central Hospital

  collaborator OTHER

• Dongying People's Hospital

  collaborator OTHER

• Rizhao People's Hospital

  collaborator OTHER

• People's Hospital of Jimo District, Qingdao

  collaborator UNKNOWN

• Liaocheng People's Hospital

  collaborator OTHER

• The Affiliated Hospital of Qingdao University

  lead OTHER

Principal Investigators

• Zhou Yanbing, MD · The Affiliated Hospital of Qingdao University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-11-01

Primary Completion

2021-11-30

Completion

2023-11-30

Countries

• China

Study Locations